In head and neck squamous cell carcinoma (HNSCC), apigenin reverses resistance to cetuximab by inhibiting extracellular signal-regulated kinase 1/2 (ERK1/2) and blocking RAS-Mitogen-activated protein kinase (MAPK) pathway [52]. Here, MAPK3 is linked to head and neck squamous cell carcinoma.